Fresenius Medical Care AG research snapshot
FMS AI stock analysis currently reads Fresenius Medical Care as the largest global dialysis products and services company, with a 2025 profitability recovery, still-elevated net debt, and a cautious 2026 growth outlook. At the July 12, 2026 data cutoff, FMS traded near $24.02 with a verified market capitalization near $12.90 billion. FY2025 revenue reached EUR 19.63 billion and reported net income rose to EUR 978 million, while 2026 guidance calls for broadly flat revenue and operating income in a positive to negative mid-single-digit range at constant currency. This FMS AI stock analysis uses scenario ranges and source-backed checks, not a certain price prediction, and is for informational use only.
Current price
$24.02
Market cap
$12.90 billion
AI score
67 / 100
Rating
Global dialysis leader with 2025 margin recovery, low valuation, flat 2026 growth guide, and policy-sensitive reimbursement risk
Trend status
Mildly constructive short-term trend near the mid-$20s, with price around the longer moving averages and still well below the 52-week high
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Fresenius Medical Care runs a global kidney-care platform spanning dialysis clinics, dialyzers and machines, and related products, with recurring patient need and multi-country operating scale. | High |
| Moat | Moat sources include clinic density, dialysis product manufacturing scale, physician and payer relationships, installed base for machines and disposables, and regulatory know-how. Reimbursement rules and regional competition still cap pricing power. | Medium-high |
| Management | CEO Helen Giza has driven FME25+ savings, debt reduction, portfolio focus, FME Reignite, 5008X CAREsystems rollout, and capital returns including buybacks and dividends. | Medium-high |
| Financial trend | FY2025 revenue rose about 2% to EUR 19.63 billion, reported net income rose 82% to EUR 978 million, free cash flow reached EUR 1.78 billion, and net leverage fell to 2.5x. Q1 2026 showed about 4% organic revenue growth and 10% operating income growth with a flat full-year revenue guide. | High |
| Valuation | At $24.02, verified math shows about 12.6x TTM EPS of $1.91, 0.86x book value near $28.07, roughly 6.7x free cash flow per ADR share, and about a 3.6% dividend yield. | Medium-high |
| Technical trend | FMS sits in the mid-$20s, above recent 50-day snapshots near the low-$22s and close to 200-day references near the mid-$23s, with RSI around 60 to 63 and a 52-week range of about $20.02 to $27.64. | Medium |
| Risk level | Risk is moderate to high for a defensive healthcare name: Medicare and commercial reimbursement, labor inflation, clinic utilization, product mix, net debt, FX translation on the ADR, and execution of FME Reignite all matter. | Medium-high |
| AI confidence | Descriptive confidence is high because company releases and market data align on the major facts. Forecast confidence is lower because 2026 guidance is flat and policy can reprice the multiple. | High data confidence |
| Investment certainty | FMS looks like a watchlist value and turnaround name with cash generation, not a high-certainty growth compounder at the current guide. | Medium |
FMS AI stock forecast
The FMS AI stock forecast is scenario math, not a guaranteed target. Using the July 12, 2026 research cutoff, a $24.02 ADR price, TTM EPS of $1.91, 537.13 million ADR shares, and a three-year model with 8%/4%/0% growth and 16x/12x/8x exit PE assumptions, the tested outcomes span about $38.50 bullish, $25.80 base, and $15.30 bearish before dividends.
$36 to $40
More likely if operating income holds near the upper half of the 2026 mid-single-digit band, free cash flow stays near EUR 1.7 billion or better, net leverage stays at or below 2.5x, 5008X adoption supports product mix, and the market values FMS near 16x higher EPS.
$24 to $28
More likely if revenue stays broadly flat, earnings grow only modestly from efficiency and mix, dividend and buyback capacity continue, and the ADR trades near 12x forward earnings with a mid-3% yield.
$14 to $17
More likely if reimbursement pressure, labor costs, lower clinic utilization, FX, or leverage concerns compress earnings growth toward zero and the market re-rates FMS toward a high-single-digit PE.
FMS AI technical analysis
FMS AI technical analysis is mildly constructive but not extended as of the July 12, 2026 data cutoff. The ADR was near $24.02 after early-July quotes around $23.91 to $24.02, above Chartmill 50-day and 100-day snapshots near $22.4 to $22.7 and close to a 200-day reference near $23.54. Momentum was constructive rather than euphoric, with RSI readings near 60 to 63 and a 52-week range of about $20.02 to $27.64.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $24.02 | Morningstar and Yahoo Finance snapshots placed FMS near $24.02 around July 10, 2026, with previous close references near $23.91. |
| Near support | $23.40 to $23.60 | The 200-day area near $23.54 and recent consolidation in the mid-$23s form the first support band. |
| Deeper support | $22.00 to $22.50 | The 50-day area near $22.4 and the lower end of the recent range matter if the mid-$23s fail. |
| Resistance | $25.50 to $27.70 | Overhead supply sits through the mid-$20s into the 52-week high zone near $27.64 to $27.70. |
| Moving averages | 50-day near $22.4, 100-day near $22.7, 200-day near $23.54 | Chartmill snapshots showed price above the 50-day and 100-day averages and close to the 200-day reference. |
| Momentum | RSI near 60 to 63 | Investing.com cited RSI(14) near 63.3 in early July, while Chartmill and TipRanks snapshots were closer to 60 to 62. |
| Volume | Average volume near 0.75 million ADR shares | Yahoo and Morningstar snapshots placed average volume roughly in the 750,000 share range, useful for judging breakouts. |
| Volatility | $20.02 to $27.64 52-week range | The range shows recovery from the low-$20s but also leaves room for multiple compression if the flat 2026 guide disappoints. |
| Invalidation | Close below $22.00, then $20.00 | A decisive close below the $22 area would weaken the constructive mid-range setup. A break of the $20 52-week low zone would invalidate the recovery thesis on the chart. |
FMS AI trading strategy
The FMS AI trading strategy below is a rules-based planning framework for risk control, not personal investment advice. It combines price confirmation with evidence that Fresenius Medical Care can hold 2026 operating income, free cash flow, and leverage targets while advancing FME Reignite.
Watch for FMS to hold the $23.40 to $23.60 support band and break above $25.50 on volume above the roughly 0.75 million ADR share reference. Confirmation improves if subsequent quarters keep operating income inside the guided mid-single-digit band and net leverage stays near 2.5x.
Treat a failed breakout back below $23.40 as a warning. A close below $22.00 invalidates the cleaner trend setup.
If FMS pulls back toward $22.00 to $22.50 without a reimbursement shock or leverage setback, compare the lower price with free cash flow, dividend capacity, FME Reignite progress, and 5008X rollout milestones.
Do not average down without a defined exit. A policy, labor, or FX reset matters more than the apparent discount to the mid-$20s.
Track quarterly revenue versus the flat 2026 guide, operating income versus the EUR 2.21 billion 2025 base, free cash flow, net debt and lease liabilities, net leverage, U.S. same-market treatment growth, Care Delivery and Care Enablement margins, dividend coverage, and buyback pace.
Reduce confidence if earnings depend mainly on one-time items while organic volume, cash conversion, or leverage trend worsen.
Investment research summary
Patients, payers, hospitals, and health systems pay Fresenius Medical Care for dialysis treatments, machines, dialyzers, and related kidney-care products because end-stage kidney disease care is medically necessary, recurring, and operationally complex at scale.
The moat is built from clinic networks, manufacturing scale in dialyzers and machines, installed product bases, physician relationships, payer contracting, and regulatory complexity. It can narrow if reimbursement falls faster than productivity gains or product innovation lags peers.
The thesis fails if U.S. or international reimbursement resets lower, clinic utilization stalls, labor inflation outruns rates, product mix disappoints, FX hurts ADR holders, leverage rises again, or FME Reignite savings fade after 2025.
Helen Giza and the leadership team have emphasized profitability recovery, FME25+ savings, debt reduction, portfolio focus, 5008X rollout, and capital returns. The key test is whether the company can protect margins when 2026 revenue is guided as broadly flat.
Dialysis demand is tied to aging, diabetes, hypertension, and chronic kidney disease. The long-term need is durable, but growth is not a pure volume story because mortality, home dialysis mix, reimbursement policy, and product innovation all shape economics.
At about 12.6x TTM EPS, 0.86x book, high single-digit free cash flow multiple, and a mid-3% dividend yield, FMS is priced more like a turnaround cash generator than a premium healthcare compounder. Margin of safety depends on holding leverage and earnings if growth stays flat.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| FMS price | About $24.02 around July 10, 2026, with previous close references near $23.91 and a 52-week range of $20.02 to $27.64 | Yahoo Finance and Morningstar FMS quote | July 12, 2026 |
| Market capitalization | $12.90 billion, verified as $24.02 x 537.13 million ADR shares with 0.01% variance | Yahoo Finance key statistics and financial_rigor.py | July 12, 2026 |
| Shares outstanding | 537.13 million ADR shares outstanding; company share capital is 268.56 million ordinary shares as of May 21, 2026 | Yahoo Finance key statistics and company share data | July 12, 2026 |
| FY2025 revenue | EUR 19.628 billion company-reported FY2025 revenue, cross-validated against Macrotrends USD revenue of $22.207 billion | Fresenius Medical Care FY2025 results release | July 12, 2026 |
| FY2025 net income and EPS | EUR 978 million reported net income attributable to shareholders, basic EPS EUR 3.36, and EUR 4.28 EPS excluding special items | Fresenius Medical Care FY2025 results release | July 12, 2026 |
| FY2025 free cash flow and leverage | Free cash flow EUR 1.782 billion; total net debt and lease liabilities EUR 9.196 billion; net leverage 2.5x at year-end 2025 | Fresenius Medical Care FY2025 results release | July 12, 2026 |
| Q1 2026 operating update and 2026 outlook | About 4% organic revenue growth and 10% operating income growth in Q1 2026; full-year 2026 guide is broadly flat revenue and operating income in a positive to negative mid-single-digit range at constant currency versus EUR 19.628 billion revenue and EUR 2.212 billion operating income bases | Fresenius Medical Care Q1 2026 press release | July 12, 2026 |
| Valuation ratios | Verified PE 12.58x on $1.91 TTM EPS, PB 0.86x on about $28.07 book value per share, P/FCF about 6.7x on an approximate $3.60 ADR free-cash-flow estimate, and dividend yield about 3.62% on a $0.87 forward dividend reference | Yahoo Finance key statistics and financial_rigor.py | July 12, 2026 |
| Technical indicators | Chartmill listed SMA50 near 22.4, SMA100 near 22.7, SMA200 near 23.54, and RSI(14) near 60.6; Investing.com showed RSI near 63.3 in early July | Chartmill and Investing.com FMS technical pages | July 12, 2026 |
This FMS AI stock analysis is an informational research tool only and is not investment advice, a recommendation, or an offer to buy or sell any security. Forecast ranges are scenario estimates based on public data as of the stated cutoff and can be wrong. Markets, reimbursement policy, currency translation, company results, and technical levels can change without notice. Do your own research and consider speaking with a licensed financial adviser before making investment decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
